Amity Institute of Biotechnology, Amity University Uttar Pradesh Lucknow Campus, Uttar Pradesh, India.
Department of Applied Science, Indian Institute of Information Technology, Allahabad, Uttar Pradesh, India.
Environ Sci Pollut Res Int. 2021 Aug;28(30):40431-40444. doi: 10.1007/s11356-020-12200-1. Epub 2021 Jan 15.
The outbreak of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected the entire world with its infectious spread and mortality rate. The severe cases of coronavirus disease 2019 (COVID-19) are characterized by hypoxia and acute respiratory distress syndrome. In the absence of any specific treatment, just the preventive and supportive care options are available. Therefore, much focus is given to assess the available therapeutic options not only to avoid acute respiratory failure and hypoxia but also to reduce the viral load to control the severity of the disease. The antimalarial drug hydroxychloroquine (HCQ) is among the much-discussed drugs for the treatment and management of COVID-19 patients. This article reviews the therapeutic potential of HCQ in the treatment of COVID-19 based on the available in vitro and clinical evidence, current status of registered HCQ-based clinical trials investigating therapeutic options for COVID-19, and environmental implications of HCQ.
新型严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的爆发以其传染性传播和死亡率影响了整个世界。2019 年冠状病毒病（COVID-19）的重症病例以缺氧和急性呼吸窘迫综合征为特征。在没有任何特定治疗方法的情况下，仅提供预防和支持性护理选择。因此，人们非常关注评估现有的治疗选择，不仅是为了避免急性呼吸衰竭和缺氧，也是为了降低病毒载量以控制疾病的严重程度。抗疟药物羟氯喹（HCQ）是治疗 COVID-19 患者的备受关注的药物之一。本文根据现有的体外和临床证据，正在进行的基于 HCQ 的 COVID-19 治疗选择临床试验的现状，以及 HCQ 的环境影响，综述了 HCQ 在治疗 COVID-19 方面的治疗潜力。
